Novartis Heart Drug Pelacarsen Fails to Meet Primary Goal

Swiss pharmaceutical giant Novartis has hit a setback in its cardiovascular development pipeline. On Thursday, the company announced that its experimental drug, pelacarsen, failed to meet its primary endpoint in a late-stage clinical trial aimed at reducing the risk of major adverse cardiovascular events in patients with established cardiovascular disease and elevated lipoprotein(a) levels.

Pelacarsen, which Novartis acquired through its $5.8 billion purchase of The Medicines Company in 2020, was designed to lower levels of lipoprotein(a), or Lp(a)—a genetically determined lipid particle that is known to increase the risk of heart attacks and strokes. For years, the drug was viewed as a high-potential asset that could address a significant, underserved patient population for whom traditional cholesterol-lowering treatments, such as statins, are often insufficient.

In a brief statement, Novartis indicated that while the drug did not achieve statistical significance on its primary goal, the company plans to share the full data from the HORIZON trial at an upcoming medical conference. The company noted that it is currently reviewing the trial results to determine the next steps for the program. This lack of clear success comes as a disappointment to investors who had hoped the drug would serve as a key growth driver for the pharmaceutical firm’s cardiovascular portfolio.

The pharmaceutical industry often faces high levels of risk when testing new therapies for chronic conditions. Trials of this magnitude, which follow patients over several years, are designed to prove that lowering a specific biological marker actually leads to better health outcomes, such as fewer heart attacks or reduced mortality. When a drug successfully lowers the target marker but fails to improve overall clinical outcomes, it creates a difficult path forward for regulatory approval.

Following the announcement, Novartis shares saw modest movement as analysts began to weigh the implications of the trial outcome. The failure of pelacarsen to demonstrate a clear benefit suggests that the relationship between lowering Lp(a) levels and reducing heart disease risk remains complex. This finding may also impact other companies currently working on similar therapies targeting the same genetic marker, as it raises questions about the optimal way to translate lipid-lowering efforts into tangible patient benefits.

Despite this hurdle, Novartis continues to maintain a robust pipeline of medicines across multiple therapeutic areas, including oncology, immunology, and neurology. The company has been shifting its strategic focus toward high-growth, innovative medicines, moving away from more commoditized business units. The result of the pelacarsen trial marks a rare clinical miss for the Basel-based company, which has seen success with other cardiovascular treatments, such as Entresto, a drug used to treat heart failure.

As the medical community awaits the detailed data, the conversation will likely shift toward whether there are specific subgroups of patients within the trial who may have derived a benefit from the treatment. Researchers often conduct post-hoc analyses of clinical data to see if a drug performs better in patients with specific characteristics, though such findings rarely carry the same weight as the primary trial goal in the eyes of regulators like the U.S. Food and Drug Administration (FDA).

For now, the future of pelacarsen remains uncertain. Novartis has not yet stated whether it intends to abandon the drug or pursue further studies. The company will likely face questions from shareholders during its next quarterly earnings call regarding how this development affects its long-term financial guidance and its commitment to the cardiovascular drug space.

Consult a healthcare professional. This is not financial advice.